Pulse Biosciences EVP & GM of Dermatology Ed Ebbers resigns; position eliminated

PULSE BIOSCIENCES, INC.

Ed Ebbers resigned as EVP & GM of Dermatology effective March 18, 2022; role eliminated in streamlining effort.
Severance includes six months' base salary in 12 semi-monthly installments, plus $28,318 in lieu of 2022 cash bonus.
Unvested equity awards accelerating over 12 months from separation date; COBRA health benefits continued.
Company expects to enter a consulting arrangement with Ebbers for a smooth transition.
Resignation not related to any disagreement over operations, policies, or practices.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Ed Ebbers

Executive Vice President and General Manager of Dermatology

PLSE · PULSE BIOSCIENCES, INC.

Effective: 2022-03-18
Filed: March 21, 2022, 7:59 PM ET

On March 18, 2022, the Company and Mr. Ed Ebbers, Executive Vice President and General Manager of Dermatology, agreed that he would resign from the Company, effective as of March 18, 2022

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Ed Ebbers resigned as Executive Vice President and General Manager of Dermatology at PULSE BIOSCIENCES, INC..

Action: resigned
Role: Executive Vice President and General Manager of Dermatology

Exact text from the filing

On March 18, 2022, the Company and Mr. Ed Ebbers, Executive Vice President and General Manager of Dermatology, agreed that he would resign from the Company, effective as of March 18, 2022

View on SEC.gov

PULSE BIOSCIENCES, INC. filing history →

Source: SEC EDGAR

accession 0001625101-22-000010

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.